Table 1.
Antibiotic therapy in inflammatory bowel diseases
| Ref. | Year | Antibiotics | Duration | Result |
| Crohn’s disease-primary therapy | ||||
| Ursing et al[53] | 1982 | Metronidazole 800 mg/d | 16 wk | No difference from sulfasalazine |
| Sutherland et al[54] | 1991 | Metronidazole 10 or 20 mg/kg | 16 wk | Superior to placebo (↓ CDAI), no difference in remission |
| Colombel et al[55] | 1999 | Ciprofloxacin 500 mg 2 × d | 6 wk | No difference from mesalamine |
| Arnold et al[56] | 2002 | Ciprofloxacin 500 mg 2 × d | 6 mo | Superior to placebo (CDAI) |
| Prantera et al[57] | 1996 | Ciprofloxacin 500 mg 2 × d + metronidazole 250 mg 4 × d | 12 wk | No difference from prednisolone |
| Greenbloom et al[58] | 1998 | Ciprofloxacin 500 mg 2 × d + metronidazole 250 mg 3 × d | 10 wk | Uncontrolled, 68% remission |
| Leiper et al[59] | 2000 | Clarithromycin 250 mg 2 × d | 4 wk | Uncontrolled, 64% response, 48% remission |
| Steinhart et al[60] | 2002 | Ciprofloxacin 500 mg 2 × d + metronidazole 250 mg 3 × d | 8 wk | No improvement over budesonide alone (33% vs 38% remission) |
| Crohn’s disease-prevention of postsurgical relapse | ||||
| Rutgeerts et al[61] | 1995 | Metronidazole 20 mg/kg | 12 wk | ↓ clinical relapse 1 yr vs placebo |
| Rutgeerts et al[62] | 2005 | Ornidazole 1 g/d | 52 wk | ↓ severe endoscopic relapse vs placebo |
| Ulcerative colitis-primary therapy | ||||
| Turunen et al[63] | 1999 | Cipro 500 mg 2 × d | 6 mo | Superior to placebo |
| Mantzaris et al[64] | 1997 | Cipro 500 mg 2 × d | 6 mo | No benefit vs placebo |
| Casellas et al[65] | 1998 | Amoxicillin 1 g/ Clavulanic acid 250 mg | 5 d | ↓ mucosal IL-8 and eicosanoids vs placebo |
| Turner et al[66] | 2014 | metronidazole, amoxicillin, doxycycline (Paediatrics) | Remission (46.6%) | |
| Pouchitis | ||||
| Shen et al[67] | 2001 | Metronidazole 20 mg/kg or Cipro 500 mg 2 × d | 6 mo | Both effective, Cipro > metronidazole |
| Gionchetti et al[68] | 2000 | Cipro 500 mg 2 × d and Rifaximin 1 g 2 × d | 5 d | 89% response, 33% remission, uncontrolled |